531726
Panch.Organics financials
- Market cap
- ₹144 Cr
- Sector
- Healthcare
What Panch.Organics does
Panchsheel Organics manufactures and exports APIs, intermediates, and finished formulations (human and veterinary) from its multipurpose manufacturing unit in Indore, Madhya Pradesh, backed by an in-house R&D setup. It also operates two other Indore manufacturing units, Suneeta Chemicals and Paramount Organics, and a GMP-approved formulations unit, Gene Biotech Pvt Ltd, in Paonta Sahib, Himachal Pradesh, which offers customized manufacturing under private label and packaging. The company sells to domestic manufacturers and MNCs such as Zydus, Abbott, Swiss Garnier and Ajanta Pharma, and exports to more than 15 countries. It is building a new fermentation plant intended to add capabilities in probiotics, antibiotics, anti-cancer products and enzymes.
Segments
- Active Pharmaceutical Ingredients (APIs)
- Intermediates
- Finished Formulations
- Fermentation-based products
- Manufacturing units
- 3 (main Indore facility plus Suneeta Chemicals and Paramount Organics, both Indore) + 1 formulations unit (Gene Biotech, Himachal Pradesh)
- Manufacturing blocks (main plant)
- 4
- Constructed manufacturing area (main plant)
- 6,100 sq. mt.
- Export reach
- 15+ countries
- Product portfolio (API current profile)
- 10 listed APIs
- New fermentation plant construction progress
- 50% of civil work complete (as of Q2 FY24)
Quarterly results
Q1 FY27: revenue up 4.7%, net profit down 18.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27 | 26 | 28 | 24 | 25 −7% | 27 +2% | 31 +10% | 25 +5% |
| EBITDA | 5 | 5 | 5 | 4 | 4 −32% | 4 −17% | 2 −49% | 3 −11% |
| Net profit | 4 | 4 | 3 | 3 | 3 −31% | 4 +0% | 2 −46% | 2 −19% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −25.2% 1Y
1Y: ₹145.65 on 10 Sept 2025 → ₹109. High ₹146.8 (22 May 2026), low ₹90.2 (30 Mar 2026).
Financials, as filed
Revenue grew 1.1% a year over 3 years, FY23 to FY26. Operating margin narrowed to 12.6%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹103 Cr | ₹105 Cr | ₹108 Cr | ₹107 Cr |
| Operating profit | ₹20 Cr | ₹19 Cr | ₹19 Cr | ₹13 Cr |
| Operating margin | 19.4% | 18.0% | 17.5% | 12.6% |
| Interest | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Net profit | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹11 Cr |
| Net margin | 13.6% | 13.4% | 13.0% | 10.2% |
| Cash from operations | ₹0 Cr | ₹10 Cr | ₹4 Cr | ₹10 Cr |
| Free cash flow | ₹-4 Cr | ₹0 Cr | ₹-12 Cr | ₹3 Cr |
| ROCE | 26.0% | 17.0% | 14.0% | 10.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹5 Cr | ₹10 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr |
| Reserves | ₹35 Cr | ₹37 Cr | ₹84 Cr | ₹112 Cr | ₹125 Cr | ₹128 Cr |
| Borrowings | ₹4 Cr | ₹4 Cr | ₹6 Cr | ₹6 Cr | ₹4 Cr | ₹6 Cr |
| Other liabilities | ₹14 Cr | ₹22 Cr | ₹21 Cr | ₹28 Cr | ₹29 Cr | ₹25 Cr |
| Total liabilities | ₹58 Cr | ₹74 Cr | ₹123 Cr | ₹159 Cr | ₹171 Cr | ₹172 Cr |
| Fixed assets | ₹7 Cr | ₹7 Cr | ₹8 Cr | ₹14 Cr | ₹19 Cr | ₹20 Cr |
| Capital work in progress | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹6 Cr | ₹17 Cr | ₹17 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹49 Cr | ₹65 Cr | ₹111 Cr | ₹137 Cr | ₹135 Cr | ₹135 Cr |
| Total assets | ₹58 Cr | ₹74 Cr | ₹123 Cr | ₹159 Cr | ₹171 Cr | ₹172 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 5% to 7,966.
- Promoters
- 56.1%
- Public
- 43.9%
Since Jun 2025
- Public +0.01 pp
- Promoters 0.00 pp
- DIIs 0.00 pp
How it drifted, 12 quarters
Over this window promoters fell from 58.1% to 56.1% — −2.0 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 58.1%, Public 41.9%.Dec '23: Promoters 58.1%, Public 41.9%.Mar '24: Promoters 58.1%, Public 41.9%.Jun '24: Promoters 56.1%, Public 43.9%.Sep '24: Promoters 56.1%, DIIs 1.1%, Public 42.7%.Dec '24: Promoters 56.1%, DIIs 1.1%, Public 42.7%.Mar '25: Promoters 56.1%, DIIs 1.0%, Public 42.9%.Jun '25: Promoters 56.1%, Public 43.9%.Sep '25: Promoters 56.1%, Public 43.9%.Dec '25: Promoters 56.1%, Public 43.9%.Mar '26: Promoters 56.1%, Public 43.9%.Jun '26: Promoters 56.1%, Public 43.9%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Dheeraj Kumar Lohia +0.12 pp 2.17% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Panch.Organics above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Rajesh Abhaychand Turakhia | 16.16% | unchanged |
| Kishore Abhaychand Turakhia | 16.11% | unchanged |
| Mahendra A Thrakhia | 16.10% | unchanged |
| Turakhia Mahendra Abhaychand Huf . | 2.71% | unchanged |
| Turakhia Rajesh Abhaychand Huf . | 2.71% | unchanged |
| Turakhia Kishor Abhaychand Huf . | 2.33% | unchanged |
| Dheeraj Kumar Lohia | 2.17% | +0.12 pp |
| Michael Dsouza | 2.02% | unchanged |
| Investor Education And Protection Fund Authority Ministry Of Corporate Affairs | 1.26% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
Growth trapTo justify its price of ₹109, this stock must grow earnings at 8% every year for 7 years. Our analysis caps realistic growth at ~-8%. At that growth it is worth ₹43 — downside of 60%.
- Growth the price implies
- 8.5% a year
- for 7 years, fading to 4%
- It has actually compounded at
- -8.3% a year
- net profit, FY23–FY26
- The gap
- 0.2 pp
- -60% downside if it only repeats history
Learn to analyse Panch.Organics
Guides on how to read this kind of business and the numbers that matter.